ArticleThe Journal of antimicrobial chemotherapy2026
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Broadly Defined Antibiotic Adjuvants forThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesUnderstand how mutations upstream of pvdS and fecI in Pseudomonas aeruginosa PAO1 lead to reduced susceptibility to cefiderocol, a siderophore cephalosporin. MATERIALS AND
methodsWhole-genome sequencing, gene complementation and inactivation, mRNA expression, siderophore quantification and supplementation were carried out with mutants that showed reduced susceptibility to cefiderocol.
resultsWhole-genome sequencing, combined with gene complementation studies, with isolated mutants that showed 4-fold reduced susceptibility to cefiderocol identified mutations within the Fur-box of promoter regions upstream of pvdS and fecI. The pvdS promoter mutation led to increased pvdS transcription, resulting in increased pyoverdine production, as well as reduced transcription of other iron transport-related genes, including piuA an iron transporter responsible for cefiderocol uptake. The down-regulation of piuA, rather than competition for iron between pyoverdine and cefiderocol, was responsible for the decreased cefiderocol susceptibility. The fecI mutant demonstrated increased transcription of fecI and fecA, and the expression level of piuA in the fecI mutant was not related to reduced cefiderocol susceptibility, indicating a different mechanism for the reduced cefiderocol susceptibility in this mutant. Sequence analyses of over 35 000 clinical P. aeruginosa isolates did not identify isolates with the pvdS mutation, and only one isolate with the fecI mutation.
conclusionsThese data highlight different mechanisms by which P. aeruginosa attempts to evade the action of cefiderocol by exploiting the complexities of iron haemostasis in bacteria. The absence of such mutants in the clinic suggests that such mutations may be detrimental for P. aeruginosa to survive in the clinical environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.